obinutuzumab,zanubrutinib,Lenalidomide,Rituximab
beigene,roche
['rosewood', 'zanubrutinib', 'obinu', 'leusm', 'lymphoma', 'lymsm', 'follicular']
#17icml pier zinzani, university of bologna shows analysis of the rosewood study of zanubrutinib + obinutuzumab in r/r follicular lymphoma. n=217. est os rate at 24 months = 77.3% (zan+obin) &amp; 71.4% (obin), with median os =nr (zan + obin) &amp; 34.6 months (obin). #lymsm #leusm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm